Nivolumab [93] and pembrolizumab [83], anti-PD-1 checkpoint inhibitor monoclonal antibodies, have been shown to improve overall survival compared to platinum-based chemotherapy in advanced NSCLC patients (Table 6). Here, PDCD1 is linked to non-small cell lung carcinoma.